Prudential Financial
LXEO icon

Prudential Financial’s Lexeo Therapeutics LXEO Stock Holding History

Prudential Financial’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$53.9K Buy
+11,585
New +$62.7K ﹤0.01% 2411

Other funds holding LXEO

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Prudential Financial's LXEO Position: Q2 2026 in Review

Prudential Financial opened a new position in Lexeo Therapeutics (LXEO) in Q2 2026: 11,585 shares worth $53.9K. The stake represents ﹤0.01% of the portfolio and ranks #2411 among its holdings.

142 funds tracked by Wall St. Rank hold LXEO as of Q2 2026.

  • Prudential Financial held 11,585 shares of Lexeo Therapeutics worth $53.9K as of Q2 2026.
  • Lexeo Therapeutics was a new Prudential Financial position in Q2 2026.
  • Lexeo Therapeutics made up ﹤0.01% of Prudential Financial's portfolio in Q2 2026, its #2411 holding.
  • 142 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q2 2026.

Based on Prudential Financial's 13F filing for Q2 2026, filed 12 Aug 2026.